506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
Study Information
Alliance Study ID: CALGB-69803
NCT Study ID (ClinicalTrials.gov): NCT00004239
Alliance Committee: Experimental Therapeutics
Disease or Cancer Type: Hematologic Malignancies (General / Unspecified)
Alliance Study Chair: Todd M. Zimmerman, MD
Status: TERMINATED
Study Description
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
PURPOSE: Phase I trial to study the effectiveness of 506U78 in treating patients who have hematologic cancer and kidney or liver impairment.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information